Application of immunomodulator in preparation of composition for treating animal cancer
The combination of Poly IC and QS-21 immunomodulators activate TLR3 receptors, promote T cell tumor infiltration, and solve the problems of inappropriate targets, difficult dose determination and high cost in canine tumor treatment, achieving It has a strong broad-spectrum and low-cost anti-tumor effect, and is suitable for pet tumor treatment.
Patent Information
- Application Number
- CN202411060743.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-05
AI Technical Summary
The existing immunotherapy targets in dog tumor treatment are not applicable, the dosage is difficult to determine, the price is high, and the lack of anti-breast tumor drugs suitable for pets leads to limited therapeutic effects and feasibility.
The combination of Poly IC and QS-21 is used as an immunomodulator to activate antigen presenting cells through TLR3 receptors, promote tumor infiltration of CD4+T and CD8+T cells, inhibit tumor growth, and use liposomes as carriers to reduce side effects , improve efficacy and safety.
It has achieved a strong broad-spectrum, low-cost and easy-to-operate anti-tumor effect, especially for canine breast cancer. The effect lasts for a long time after the drug is discontinued, and is safe and suitable for pet tumor treatment.
Smart Images

Figure CN118949024A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of tumor immunotherapy, and in particular to the application of an immunomodulator in the preparation of a composition for treating animal cancer. Background Art
[0002] Dogs are the most common companion animals. With the rapid development of pet nutrition and welfare, the life span of pet dogs has gradually increased. More and more tumors occur in middle-aged and elderly dogs, causing great pain to pets and owners. Common types of canine tumors include breast tumors, skin and soft tissue tumors, etc.
[0003] Canine mammary tumor (CMT) is one of the most common tumor diseases in pet clinics, accounting for about 25% to 42% of tumor diseases in female dogs. Affected by factors such as age, genetics, environmental pollution, and feeding habits, canine mammary tumors show characteristics such as youth, complexity, and high malignancy. At present, the clinical treatment of canine mammary tumors is mainly surgery, combined with chemotherapy to effectively reduce its recurrence and metastasis rate.
[0004] Veterinary clinics use surgery as the main treatment for CMT. Since simple surgical treatment is difficult to eradicate the lesions, tumors often metastasize and spread, resulting in a short survival period after CMT surgery and a recurrence rate of up to 58%. At the same time, CMT mainly occurs in elderly dogs, and a large number of cases are difficult to perform surgery due to organ function limitations. The promotion of chemotherapy can effectively supplement the limitations of surgical treatment and improve the effectiveness and applicability of clinical treatment. Commonly used chemotherapy drugs mainly include alkylating agents, platinum compounds, anti-tubulin, anti-tumor antibiotics, antimetabolites, targeted therapy drugs and other drugs. However, current studies have shown that the most commonly used alkylating agents and platinum drugs for pet tumors are not effective against CMT.
[0005] Foreign countries have approved chemical small molecule drugs such as masitinib and togranib phosphate as tumor drugs for pet clinical use, but my country has not yet approved the marketing of pet-specific anti-cancer drugs. There is a situation where there are no legal and compliant anti-breast tumor drugs for use in pet clinical practice. Therefore, it is necessary to accelerate the creation of anti-breast tumor drugs for dogs to meet the demand for anti-cancer drugs in pet clinical practice, improve the quality of life and welfare of sick dogs, and provide support for promoting the rapid development of the pet economy.
[0006] Canine breast cancer has many biological similarities with human breast cancer. Therefore, some people have proposed that immunotherapy can be used to treat canine breast cancer. Although there is a lot of research foundation for tumor immunotherapy, there are still many problems to be solved in applying immunotherapy to canine tumor treatment. (1) Existing immunotherapy targets are not completely applicable to dogs, and new targets need to be explored. (2) There are many breeds of dogs, and the body sizes of different breeds vary greatly. The dosage problem of immunotherapy is difficult to solve, and more experimental data is needed for exploration. (3) The high price is a very critical issue for immunotherapy in canine tumor treatment. Most current immunotherapies require one-on-one precision treatment, which requires high technology and conditions of pet hospitals during treatment, and the drugs are expensive.
[0007] In view of this, the present invention is proposed. Summary of the invention
[0008] The purpose of the present invention is to provide an application of an immunomodulator in the preparation of a composition for treating animal cancer to solve the above technical problems.
[0009] The present invention is achieved in that:
[0010] In a first aspect, the present invention provides the use of an immunomodulator in the preparation of a composition for treating animal cancer, the immunomodulator comprising: Poly IC and QS-21 in a mass ratio of (1.3 to 60):1, the cancer is breast cancer, melanoma, liver cancer, colon cancer, ovarian cancer or lung cancer, and the animal is a dog, mouse or rat.
[0011] In a second aspect, the present invention provides an application of a composition in the preparation of a drug for treating animal cancer, the composition comprising: an immunomodulator and a pharmaceutically acceptable carrier, the immunomodulator comprising: Poly IC and QS-21 in a mass ratio of (1.3 to 60):1, the cancer is breast cancer, melanoma, liver cancer, colon cancer, ovarian cancer or lung cancer, and the animal is a dog, mouse or rat.
[0012] The present invention has the following beneficial effects:
[0013] The present invention provides an application of an immunomodulator in the treatment of animal cancer. After being applied to the tumor tissue of a subject, the immunomodulator activates antigen presenting cells in the tumor tissue through the TLR3 receptor, further activates the immune response of the tumor microenvironment, promotes the tumor infiltration of CD4+T and CD8+T cells, and thus exerts an anti-tumor effect. Compared with existing immunotherapy, the immunomodulator provided by the present invention has the advantages of strong broad spectrum, low cost, easy operation, and good effect, and can effectively inhibit the growth of animal cancer, especially for the treatment of canine breast cancer, and is easier to promote and use.
[0014] In addition, the immunomodulator provided by the present invention can be maintained for a long time after discontinuation of the drug, and in terms of safety, there are no serious adverse events after injection, and the animal tolerance is good. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0016] Figure 1 The tumor growth curves of breast cancer in mice treated with different ratios of QS21 and Poly(I:C);
[0017] Figure 2 The statistical results of tumor weight of breast cancer mice treated with different ratios of QS21 and Poly (I:C);
[0018] Figure 3 Tumor growth curves of QS21, Poly IC alone, and their combination (AYK103);
[0019] Figure 4 The statistical results of tumor weight of QS21, Poly IC used alone and the combination of the two (AYK103) are shown in the figure;
[0020] Figure 5 The tumor growth curve is a comparison of the effects of other immune adjuvants combined with AYK103 in treating mouse melanoma;
[0021] Figure 6 This is the tumor growth curve of breast cancer in mice treated with AYK103;
[0022] Figure 7 This is the statistical result of breast cancer tumor weight in mice treated with AYK103;
[0023] Figure 8 This is a picture of breast cancer tumor tissue in mice treated with AYK103;
[0024] Fig. 9 This is the result of flow cytometry detection of the effect of AYK103 on the number of immune cells in tumor tissues;
[0025] Fig.10 This is the result of immunohistochemistry detection of the effect of AYK103 on the number of immune cells in tumor tissue;
[0026] Fig.11 This is the treatment result diagram of the first sick dog;
[0027] Fig.12 This is the treatment result diagram of the second sick dog;
[0028] Fig.13 This is the statistical result of the tumor weight of lung cancer in mice treated with AYK103;
[0029] Fig.14 This is the statistical result of liver cancer tumor weight in mice treated with AYK103;
[0030] Fig.15 This is a statistical graph of the weight of colon cancer tumors in mice treated with AYK103;
[0031] Fig.16 This is the result of in vivo fluorescence imaging of AYK103 treatment of peritoneal metastasis of ovarian cancer in mice;
[0032] Fig.17 This is the survival curve of AYK103-treated mice with peritoneal metastasis of ovarian cancer. DETAILED DESCRIPTION
[0033] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0034] The term "immunomodulator" generally refers to a substance that affects the function of the immune system. An immunomodulator can enhance or reduce an immune response. For example, an immunomodulator can be an active agent of immunotherapy, including but not limited to, for example, cytokines, granulocyte colony stimulating factor (G-CSF), interferon, imiquimod, cell membrane fragments from bacteria, chemokines, interleukins, Poly IC, QS-21, cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and recombinant, synthetic and / or natural preparations of dextran.
[0035] The terms "treat" or "treating" or "preventing" or "alleviating" or "improving" are used interchangeably herein and refer to an approach for obtaining beneficial or desired results, including but not limited to therapeutic benefit and / or preventive benefit. As used herein, a therapeutic benefit generally refers to eradication or lessening of the severity of the underlying condition being treated. Furthermore, a therapeutic benefit is achieved by eradication, lessening of severity, or reduction in the incidence of one or more physiological symptoms associated with the underlying condition, such that an improvement is observed in the subject (although the subject may still be afflicted with the underlying condition).
[0036] The term "subject" or "subject" generally refers to non-human animals, including but not limited to dogs, mice, or rats.
[0037] Poly IC, i.e. polyinosinic-polycytidylic acid, is synonymous with "Poly (I:C)". Polyinosinic-polycytidylic acid is a toll-like receptor 3 (TLR3) agonist and a synthetic double-stranded RNA (dsRNA). CAS number: 42524-50-0.
[0038] QS-21, CAS No. 141256-04-4, molecular formula: C 92 H 148 O 46 , molecular weight: 1990.14. Also synonymous with "QS21" and "Quillaja saponin 21".
[0039] In a first aspect, the present invention provides the use of an immunomodulator in the preparation of a composition for treating animal cancer, the immunomodulator comprising: Poly IC and QS-21 in a mass ratio of (1.3 to 60):1, the cancer is breast cancer, melanoma, liver cancer, colon cancer, ovarian cancer or lung cancer, and the animal is a dog, mouse or rat.
[0040] After long-term and extensive screening, the inventors found that the combined use of Poly IC and QS-21 has better anti-tumor effects than the use of Poly IC or QS-21 alone or the use of positive chemical anticancer drugs. It can inhibit the growth rate of tumors, reduce the size and weight of tumors, and can reverse the tumor immune microenvironment, increase the number of anti-tumor immune cells in tumor tissues, and transform the tumor tissue microenvironment from an immunosuppressive type to an immune-activating type, thereby exerting anti-tumor functions and inhibiting tumor growth.
[0041] In addition, the immunomodulator provided by the present invention can maintain its effect for a long time after drug withdrawal, has good safety, no serious adverse events after injection, and good tolerance. The immunomodulator also has the advantages of strong broad spectrum, low cost, and easy operation, and has broad application prospects.
[0042] The mass ratio of Poly IC to QS-21 includes, but is not limited to, 1.3:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 15:1, 16:1, 20:1, 25:1, 30:1, 35:1, 40:1, 42:1, 45:1, 48:1, 50:1, 52:1, 55:1 or 60:1, and ranges between any two.
[0043] The mass ratio of Poly IC to QS-21 in the above ratio has anti-tumor effect.
[0044] The lung cancer is selected from small cell lung cancer and non-small cell lung cancer, and the non-small cell lung cancer is selected from squamous cell carcinoma and adenocarcinoma.
[0045] In an alternative embodiment, breast cancer includes but is not limited to breast epithelial cancer;
[0046] In a preferred embodiment of the present invention, breast cancer is breast ductal carcinoma or breast lobular carcinoma.
[0047] In a preferred embodiment of the present invention, the immunomodulator includes: PolyIC and QS-21 in a mass ratio of (4-32):1; at this ratio, the anti-tumor effect is better, and it has a better effect of inhibiting tumor growth and reducing tumor weight and volume.
[0048] In a preferred embodiment of the present invention, the immunomodulator comprises: PolyIC and QS-21 in a mass ratio of (4-16):1;
[0049] In a preferred embodiment of the present invention, the immunomodulator includes: PolyIC and QS-21 in a mass ratio of (6-8): 1. Under the above ratio, the anti-tumor effect is better, and it has a better effect of inhibiting tumor growth and reducing tumor weight and volume.
[0050] In a preferred embodiment of the present invention, the composition further comprises: a pharmaceutically acceptable carrier.
[0051] The pharmaceutically acceptable carrier is selected from at least one of a protective agent, an excipient, a binder, a disintegrant, a lubricant, a flavor, a preservative, a stabilizer, a suspending agent, a dispersant and a diluent.
[0052] Examples include: protective agents, such as liposomes; excipients, such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate; binders, such as cellulose, methylcellulose, hydroxypropyl cellulose, polypropyl pyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch; disintegrants, such as starch, hydrolyzed starch, carboxymethyl cellulose, carboxymethyl cellulose calcium salt, hydroxypropyl starch, ethylene glycol starch sodium, sodium bicarbonate, calcium phosphate, calcium citrate; lubricants, such as magnesium stearate, talc, sodium lauryl sulfate; flavors, such as citric acid, mint alcohol, glycine, orange powder; preservatives such as sodium benzoate, sodium bisulfite, parabens (such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben); stabilizers such as citric acid, sodium citrate, acetic acid and polycarboxylic acids from the titriplex series, such as diethylenetriaminepentaacetic acid (DTPA); suspending agents such as methylcellulose, polyvinylpyrrolidone, aluminum stearate; dispersants; diluents such as water, organic solvents; waxes, fats and oils such as beeswax, cocoa butter; polyethylene glycol; white petrolatum, etc.
[0053] In a preferred embodiment of the present invention, the carrier is a liposome. Liposome is a nano-vesicle body with a bilayer structure formed by self-assembly of phospholipids or phospholipid-like molecules, and has a long-chain alkyl hydrophobic end.
[0054] In a preferred embodiment of the present invention, the liposome is a cationic liposome;
[0055] In a preferred embodiment of the present invention, the lipid component of the liposome is a phospholipid or a phospholipid-like molecule.
[0056] Phospholipid-like molecules refer to block polymers of bonded phospholipids with amphiphilicity, such as PCL-b-(PBrCL-g-PMPC) disclosed in patent CN202010717453.1.
[0057] In a preferred embodiment of the present invention, the lipid component in the liposome refers to: empty liposomes containing or consisting of phosphatidylcholine and sphingomyelin, wherein the phosphatidylcholine is present in an amount of 15-98% (w / w).
[0058] In a preferred embodiment of the present invention, the phospholipids are selected from glycerophospholipids and sphingomyelin.
[0059] In a preferred embodiment of the present invention, the phospholipid is selected from any one of dioleoylphosphatidylcholine (DOPC), soybean lecithin, sunflower lecithin, DSPG (distearoylphosphatidylglycerol), DPPC, HSPC (hydrogenated soybean lecithin), DSPC (distearoylphosphatidylcholine) and EPC (egg yolk lecithin) or a combination of at least two thereof; such as a combination of HSPC and DSPC, a combination of HSPC and DSPC, a combination of HSPC and EPC, and the like. Other arbitrary combinations are not described one by one herein.
[0060] In a preferred embodiment of the present invention, when the phospholipid is lecithin, the phosphatidylcholine (PC) content in the lecithin includes at least one of 15%, 30%, 35%, 50%, 60%, 70%, 80%, 90% and 98%.
[0061] In a preferred embodiment of the present invention, in the composition, the mass ratio of Poly IC, QS-21 and liposome is (1.3-60):1:(15-25). Different mass ratios affect the interaction between QS21 and liposome. QS21 has a hemolytic effect, and QS21 that can be effectively adsorbed on liposomes can significantly reduce this side effect. For example, the mass ratio of Poly IC, QS-21 and liposome is (1.3-60):1:15, (1.3-60):1:18, (1.3-60):1:20, (1.3-60):1:22, (1.3-60):1:25.
[0062] In a preferred embodiment of the present invention, in the composition, the mass ratio of Poly IC, QS-21 and liposome is (6-10):1:(15-25).
[0063] In a preferred embodiment of the present invention, the liposome is prepared from 1,2-dioleoyl-3-trimethylammonium chloride propane (DOTAP), dioleoylphosphatidylcholine (DOPC) and cholesterol (DC-Chol).
[0064] For example, 1,2-dioleoyl-3-trimethylammonium chloride propane, dioleoylphosphatidylcholine and cholesterol are mixed in a mass ratio of 1:8 to 12:3 to 4 to obtain a first mixture; the first mixture is used as a raw material to prepare liposomes by any one of an ethanol injection method, a thin film dispersion method, an ultrasonic dispersion method and a reverse evaporation method.
[0065] In some embodiments, the mixing mass ratio of 1,2-dioleoyl-3-trimethylammonium chloride propane (DOTAP), dioleoylphosphatidylcholine (DOPC) and cholesterol can be any one of 1:8:3, 1:8:4, 1:9:3, 1:9:4, 1:10:3, 1:10:4, 1:11:3, 1:11:4, 1:12:3, 1:12:4, or a range between any two of them.
[0066] In a preferred embodiment of the present invention, the composition is prepared by the following method: blending a carrier with Poly IC and QS-21. In one embodiment, Poly IC and QS-21 are first blended to obtain a mixture, and then the mixture is blended with the carrier, so that Poly IC and QS-21 are assembled in the carrier by self-assembly.
[0067] In a preferred embodiment of the present invention, when the carrier is a liposome, the particle size of the liposome is 100 to 300 nm. The particle size can be any one of 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300 nm or any two thereof. The optimal particle size for ingestion in vivo is 60-300 nm. If the particle size is too small, it is easily metabolized by the kidneys quickly, which reduces the retention time in the tumor and thus reduces the effect.
[0068] In a preferred embodiment of the present invention, the composition is a medicine;
[0069] In a preferred embodiment of the present invention, the drug is administered by injection;
[0070] In a preferred embodiment of the present invention, the drug is administered by intratumoral injection.
[0071] In a preferred embodiment of the present invention, the drug has any of the following uses:
[0072] (1) Activate the immune response of the tumor microenvironment and reverse the tumor immunosuppressive microenvironment;
[0073] (2) Inhibit tumor growth rate;
[0074] (3) reduce tumor weight;
[0075] (4) reduce tumor volume;
[0076] In a preferred embodiment of the present invention, the use of the drug to activate the immune response of the tumor microenvironment includes: promoting tumor infiltration of CD4 T and CD8 T cells;
[0077] In a preferred embodiment of the present invention, the use of the drug to activate the immune response of the tumor microenvironment is selected from at least one of the following:
[0078] (1) Increase the number of cytotoxic T cells CD8+T in tumor tissue;
[0079] (2) Increase the number of effector memory T cells CD8+T in tumor tissue;
[0080] (3) Increase the number of CD4+ T helper cells in tumor tissue;
[0081] (4) Increase the number of macrophages among antigen-presenting cells in tumor tissue;
[0082] (5) Increase the number of dendritic cells among antigen-presenting cells in tumor tissue.
[0083] In a preferred embodiment of the present invention, the final concentration of QS-21 in the composition is 50-300 μg / mL, and the final concentration can be any one of 50, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300 μg / mL or a range between any two thereof.
[0084] The final concentration of Poly I:C is 400-3000 μg / mL, and the final concentration can be any one of 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000 μg / mL or a range between any two thereof.
[0085] In a second aspect, the present invention provides an application of a composition in the preparation of a drug for treating animal cancer, the composition comprising: an immunomodulator and a pharmaceutically acceptable carrier, the immunomodulator comprising: Poly IC and QS-21 in a mass ratio of (1.3 to 60):1, the cancer is breast cancer, melanoma, liver cancer, colon cancer, ovarian cancer or lung cancer, and the animal is a dog, mouse or rat.
[0086] In a preferred embodiment of the present invention, the carrier is a liposome;
[0087] In a preferred embodiment of the present invention, the liposome is a cationic liposome;
[0088] In a preferred embodiment of the present invention, the mass ratio of Poly IC, QS-21 and liposome in the drug is (1.3-60):1:(15-25); for example, Poly The mass ratio of IC, QS-21 to liposomes is (1.3-60):1:15, (1.3-60):1:18, (1.3-60):1:20, (1.3-60):1:22, (1.3-60):1:25, (5-50):1:25, (10-25):1:25, or (10-32):1:25, and can also be any one of 1:6:16, 1:6:18, 1:6:20, 1:6:22, 1:6:24, 1:8:16, 1:8:18, 1:8:20, 1:8:22, 1:8:24, 1:10:16, 1:10:18, 1:10:20, 1:10:22, and 1:10:24, or a range between any two of them.
[0089] In a preferred embodiment of the present invention, in the composition, the mass ratio of Poly IC, QS-21 and liposome is (6-10):1:(15-25).
[0090] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0091] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0092] Example 1
[0093] This embodiment provides an immunomodulator and a drug (AYK103) comprising the immunomodulator and liposomes. Specifically, the immunomodulator is composed of Poly IC (CAS No.: 42524-50-0) and QS-21 (CAS No.: 141256-04-4) in a mass ratio of 4:1.
[0094] Liposomes were prepared by an ethanol injection method as follows: 1,2-dioleoyl-3-trimethylammonium chloride propane, dioleoylphosphatidylcholine and cholesterol were dissolved in ethanol at a mass ratio of 1:8:3, and the first immune adjuvant Poly IC was added and loaded with one syringe; the aqueous phase PBS was loaded with another syringe; the flow rate was controlled and injected into a T-type microchannel mixer to obtain a Poly IC-containing liposome solution, and the method can be referred to the literature;
[0095] The Poly IC liposome solution and the QS21 aqueous solution were mixed in proportion and then mixed by a mediator for 30 minutes to obtain the AYK103 preparation.
[0096] Example 2
[0097] This embodiment provides an immunomodulator and a medicine comprising the immunomodulator and liposomes.
[0098] Specifically, the immunomodulator is composed of Poly IC and QS-21 in a mass ratio of 8:1.
[0099] The liposomes are prepared by the following method: 1,2-dioleoyl-3-trimethylammonium chloride propane, dioleoylphosphatidylcholine and cholesterol are dissolved in ethanol at a mass ratio of 1:8:3, and the first immune adjuvant Poly IC is added and loaded with one syringe; the aqueous phase PBS is loaded with another syringe; the flow rate is controlled and injected into a T-type microchannel mixer to obtain a Poly IC-containing liposome solution. The method can be referred to the literature (Maritim S, Boulas P, Lin Y. International journal of pharmaceutics, 2021, 592: 120051.);
[0100] The Poly IC liposome solution and the QS21 aqueous solution were mixed in proportion and then mixed by a mediator for 30 minutes to obtain the AYK103 preparation.
[0101] Example 3
[0102] Compared with Example 2, the only difference is that the ratio of the immunomodulators is different. This example is composed of Poly IC and QS-21 with a mass ratio of 16:1.
[0103] Example 4
[0104] Compared with Example 2, the only difference is that the ratio of the immunomodulator is different. This example is composed of Poly IC and QS-21 with a mass ratio of 32:1.
[0105] Comparative Example 1
[0106] Compared with Example 2, the only difference is that the ratio of the immunomodulators is different. This example is composed of Poly IC and QS-21 in a mass ratio of 1:1.
[0107] Comparative Example 2
[0108] Compared with Example 2, the only difference is that the ratio of the immunomodulators is different. This example is composed of Poly IC and QS-21 in a mass ratio of 2:1.
[0109] Comparative Example 3
[0110] Compared with Example 2, the only difference is that the ingredients of the immunomodulator are different. This example is composed of Poly IC and MPLA (CAS No. 1246298-63-4, prepared by Anyikang) in a mass ratio of 4:1.
[0111] Comparative Example 4
[0112] Compared with Example 2, the only difference is that the composition of the immunomodulator is different. This example is composed of QS-21 and MPLA in a mass ratio of 1:2.
[0113] Experimental Example 1
[0114] This experimental example screens the anti-tumor effects of two active ingredients, QS-21 and Poly I:C, in different ratios.
[0115] Experimental methods:
[0116] According to the preparation method of AYK103 drug in Examples 1-4 and Comparative Examples 1-2, several drugs with different ratios were prepared. The ratios of QS21:Poly IC were 1:1, 1:2, 1:4, 1:8, 1:16, and 1:32, respectively.
[0117] Construction of 4T1 cell line breast cancer model: Mouse breast cancer cell 4T1 cell line (American Type Culture Collection, ATCC). Culture conditions: RPMI 1640 medium + 10% FBS + 1% double antibody. Mouse breast cancer cell 4T1 cell line was centrifuged at 1000r / min for 5 minutes. The cell survival rate was detected by 0.4% trypan blue exclusion method (survival rate>90%), and the cells were washed 3 times with PBS and centrifuged at 1000r / min for 5 minutes. PBS was added to adjust the cell concentration to 5×10 6 100 μl of cell suspension was inoculated into the axilla of 20 female mice. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 5th day after tumor inoculation.
[0118] Tumor volume measurement: Tumor volume is measured every three days using the tumor diameter measurement method to dynamically observe the anti-tumor activity of the test drug. The long and short diameters of the tumor are measured with a vernier caliper to calculate the tumor volume, tumor volume = 1 / 2 × long diameter × short diameter 2.
[0119] The mice were randomly divided into 8 experimental groups according to the tumor volume, as follows: 0.9% NaCl (100 μL / mouse), Vehicle (blank liposome control, 100 μL / mouse), 32:1 (Poly I:C:QS-21, Example 4), 16:1 (Poly I:C:QS-21, Example 3), 8:1 (Poly I:C:QS-21, Example 2), 4:1 (Poly I:C:QS-21, Example 1), 2:1 (Poly I:C:QS-21, Comparative Example 2), 1:1 (Poly I:C:QS-21, Comparative Example 1). There were 8 mice in each group, all of which were female. The first administration was carried out on the day after grouping (8th day after tumor implantation), with a dosage of 100 μL / mouse. The second administration was carried out on the 11th day after tumor implantation, with a dosage of 100 μL / mouse. The last administration was performed on the 14th day after tumor implantation, with a dose of 100 μL / mouse. The general conditions of the animals, such as body weight and diet, were observed daily, the weight changes of the mice were monitored, and the changes in tumor size were detected every three days.
[0120] Experimental results:
[0121] Figure 1 The results show that when the ratio of the two active ingredients PolyIC:QS21 in AYK103 is between 1:1 and 32:1, the tumor growth rate is significantly inhibited. Figure 2 The results showed that the tumor weight and volume were significantly smaller than those in the 0.9% NaCl and Vehicle groups, and among the six groups of 1:1, 2:1, 4:1, 8:1, 16:1, and 32:1, the ratios with the best anti-tumor effects were 4:1, 8:1, 16:1, and 32:1.
[0122] Experimental Example 2
[0123] Experiment on the combined use of QS-21 and Poly I:C to increase the anti-tumor effect.
[0124] Experimental methods:
[0125] According to the AYK103 preparation method in Example 1, liposomes containing only QS-21, liposomes containing only Poly I:C, and liposomes AYK103 containing QS-21 / Poly I:C were prepared, wherein the mass ratio of QS-21:Poly I:C in AYK103 was 1:8.
[0126] A mouse breast cancer model was constructed according to the method in Experimental Example 1, and the tumor volume was randomly divided into 4 experimental groups, with 8 mice in each group, all female. The first administration was performed on the day after grouping (9th day after tumor implantation), the second administration was performed on the 12th day after tumor implantation, and the last administration was performed on the 15th day after tumor implantation. The dosage was the same as in Experimental Example 1. The general conditions such as the weight and diet of the animals were observed daily, the weight changes of the mice were monitored, and the changes in tumor size were detected every three days.
[0127] Figure 3 , Figure 4 The results show that tumor growth was inhibited by injection of QS21 liposomes and Poly I:C liposomes, and the tumor growth rate after injection of Poly I:C liposomes was lower than that after injection of QS21 liposomes. However, the effects of both were not as good as those of AYK103 (QS21 / Poly I:C), indicating that the combined use of QS21 and Poly I:C has a synergistic effect.
[0128] Experimental Example 3
[0129] Comparison of the effects of other immune adjuvants used in combination with AYK103.
[0130] Three experimental groups were set up to prepare immune adjuvants MPLA+QS-21 (Comparative Example 4), MPLA+PolyIC (Comparative Example 3) and AYK103 (Example 1), respectively.
[0131] Experimental methods
[0132] 6-week-old C57BL / 6J mice were subcutaneously inoculated with 5×10 5 B16-OVA cells were used to establish a mouse melanoma subcutaneous tumor model. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 5th day after tumor implantation. The mice were randomly divided into 4 experimental groups according to the tumor volume, as follows: liposome control group (blank liposome negative control group without drug encapsulation, 100μL / mouse / time), MPLA+QS-21 (100μL / mouse / time), MPLA+PolyIC (100μL / mouse / time), AYK103 (100μL / mouse / time). There were 10 mice in each group, all of which were female. The first administration was performed on the day after grouping (9th day after tumor implantation), the second intratumoral injection was performed on the 12th day after tumor implantation, and the last intratumoral injection was performed on the 15th day after tumor implantation. The general conditions such as animal weight and diet were observed daily, the weight changes of mice were monitored, and the changes in tumor size were detected every three days.
[0133] Experimental reference Figure 5 It can be seen that among the three adjuvant combinations, AYK103 (Poly (I: C) + QS21) has the best effect in inhibiting tumor growth, with a tumor inhibition rate of about 96%.
[0134] Experimental Example 4
[0135] AYK103 inhibits the growth of mouse breast cancer.
[0136] Experimental methods:
[0137] AYK103 was prepared according to the preparation method in Example 2.
[0138] A mouse breast cancer model was constructed according to the method in Experimental Example 1. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 8th day after tumor implantation, and the mice were randomly divided into 3 experimental groups according to the tumor volume, as follows: Vehicle (100 μL / mouse), AYK103 group (100 μL / mouse), CTX group (25 mg / kg). There were 10 mice in each group, all female, and the first administration was performed on the day after grouping (8th day after tumor implantation), the second administration was performed on the 11th day after tumor implantation, and the last administration was performed on the 14th day after tumor implantation. The general conditions such as animal weight and diet were observed daily, the weight changes of mice were monitored, and the changes in tumor size were detected every three days.
[0139] Figure 6 The results show that after the injection of AYK103, tumor growth was inhibited, and the tumor growth rate of the AYK103 group was significantly lower than that of the negative control Vehicle group and the positive control chemotherapy drug cyclophosphamide CTX group. Figure 7 , Figure 8 The results showed that the tumor weight and final volume of mice in the AYK103 group were significantly smaller than those in the cyclophosphamide CTX group. These results indicate that AYK103 is more effective in inhibiting breast cancer growth than the chemotherapy drug cyclophosphamide, with a relative tumor inhibition rate of 70.4%.
[0140] Experimental Example 5
[0141] Experiment on AYK103 reversing tumor immunosuppressive microenvironment.
[0142] The experimental method is as follows:
[0143] AYK103 was prepared according to the preparation method in Example 2.
[0144] A mouse breast cancer model was constructed according to the method in Experimental Example 1. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 4th day after tumor implantation, and the mice were randomly divided into 2 experimental groups according to the tumor volume, as follows: Vehicle (100 μL / mouse), AYK103 group (100 μL / mouse). There were 8 mice in each group, all female, and the mice were administered according to the method in Example 3 after grouping. On the 2nd day after the last administration, the tumor tissue was removed for flow cytometry and immunohistochemistry.
[0145] 1) Streaming detection processing method:
[0146] Tumor tissue sampling: The mice were killed by cervical dislocation. The hair, skin and tissue of the mice were carefully separated with surgical scissors and elbow forceps. The intact breast cancer subcutaneous tumor was gently freed. After weighing, recording and taking pictures, 0.1-0.5g of each tumor tissue was retained and placed in pre-cooled 1× PBS.
[0147] Preparation of single cell fluid of tumor tissue: prepare clean 5mL EP tubes according to the group number, cut the above tumor tissue into 5mm tissue blocks in the tube, use the prepared tissue digestion solution [RPMI-1640 culture medium, 0.5mg / ml collagenase D, 0.1mg / ml DNase I], resuspend the tumor tissue with a volume of 4mL digestion solution / sample, and transfer it to the gentle MACS C tube, run program 37C_Multi_F, and after the program ends, remove the C tube from the gentle MACS tissue processor; rinse the filter with RPMI-1640, filter the grinding solution with a 70μm filter membrane, collect the cell suspension in a 10mL EP tube, centrifuge (400g, 5min, room temperature), discard the supernatant, prepare 1× red blood cell lysis solution with pure water, resuspend the cell pellet with a volume of 2mL 1× red blood cell lysis buffer / sample, let it stand at room temperature for 5min, add 5ml 1× PBS to terminate the lysis, centrifuge (400g, 5min, room temperature), and discard the supernatant;
[0148] Live / Dead staining: resuspend the cell pellet with the prepared Live / Dead diluent (Near IR is diluted with 1×PBS at a ratio of 1:500) at a volume of 100 μL Live / Dead diluent / sample, incubate at 4°C in the dark for 30 min, terminate the staining with 1 mL 1×PBS, take a small amount of cell suspension from each group of samples for use as Live / Dead single positive tubes, centrifuge (400 g, 5 min, room temperature) and discard the supernatant;
[0149] Flow cytometry antibody staining: Use the prepared mixed staining solution (PE / Cy7-CD3, FITC-CD4, BV510-CD8, PE-CD45, BV421-CD62, APC-CD206 at a ratio of 1:800, diluted with 1×PBS), resuspend the above cell pellet in a volume of 100μL mixed staining solution / sample, incubate at 4℃ in the dark for 30min, terminate staining with 1mL 1×PBS, centrifuge (400g, 5min, room temperature) and discard the supernatant. Each antibody single positive tube is stained with 0.2μL / tube of Beads for later use, and the staining method is the same as above;
[0150] Sample loading: Flow cytometer detection, first perform voltage definition on blank control tube and single positive tube, then record cell counts of each group of samples after fixing the voltage, and convert cells / g tumor unit using the sampled tumor tissue mass.
[0151] 2) Immunohistochemistry detection and processing methods:
[0152] The tumor tissue was sliced to a thickness of 4 microns and spread at 42°C. The slices were soaked in xylene I for 5 minutes, xylene II for 5 minutes, xylene III for 5 minutes, anhydrous ethanol for 1 minute, 95% ethanol for 1 minute, 75% ethanol for 1 minute, and washed with distilled water for 5 minutes. EDTA microwave heat repair for 5-8 minutes and cooled to room temperature. Endogenous peroxidase blocking solution was added, incubated at room temperature for 10 minutes, and washed with PBS buffer 3 times, 5 minutes each time. Blocking serum was added and incubated at 37°C for 30 minutes. Primary antibody was added, incubated in a 37°C wet box for 2 hours, and washed with PBS buffer 3 times, 5 minutes each time. HRP-labeled goat anti-rabbit was added, incubated at 37°C for 30 minutes, and washed with PBS buffer 3 times, 5 minutes each time. DAB colorimetric solution was prepared: 1ml B solution + 1 drop of A solution, mixed, DAB colorimetric solution was added, and observed under a microscope. Mayer'S hematoxylin was added for 30 seconds, washed with distilled water, soaked in blue solution for 1 minute, and washed with water. Dehydrate with 75%-95%-100% alcohol gradient, 1 minute per cylinder, clear with three cylinders of xylene, 2 minutes per cylinder, and seal with neutral gum.
[0153] Fig. 9 It can be seen that after the injection of AYK103, the number of cytotoxic T cells CD8+T, effector memory cytotoxic T cells Effector memory CD8+T, helper T cells CD4+T and anti-tumor M1 macrophages in the tumor tissue can be significantly increased, indicating that the immune response of the tumor tissue is activated and the increase in anti-tumor immune cells helps to kill the tumor. Fig.10 The results also proved that after injection of AYK103, the number of CD8+T cells, CD4+T cells in the tumor tissue, as well as macrophages and DC cells in the antigen-presenting cells increased significantly, indicating that the microenvironment of the tumor tissue changed from an immunosuppressive type to an immune-activating type.
[0154] Example 6
[0155] Experiment on treating breast cancer in pet dogs with AYK103 prepared in Example 2.
[0156] A single-arm trial design was used to collect 6 dogs with breast cancer from a pet hospital in Xinxiang, Henan and a pet hospital in Dalian. AYK103 was injected into the tumor or subcutaneously around the tumor. Each tumor was given 0.5-1 mL once a week. The length and width of the tumor were measured with a ruler, and the tumor volume was calculated as (length*width*width) / 2 (mm3 ). Record the tumor volume, body temperature, body weight, clinical characteristics of the test dogs: whether there is fever, whether there is redness, swelling or inflammation at the injection site, and the mental state of the animals.
[0157] The test results show:
[0158] Four of the six dogs dropped out, withdrew, or died, and two dogs underwent complete treatment. The initial clinical treatment results are shown in the following table. Fig.11 The results showed that the first dog to be treated was a Teddy dog with two lesions. After eight doses, the volumes of the two tumors were reduced by 65% and 67% respectively compared with before treatment. Three months after stopping the drug, the tumors were reduced by 90% and 73% respectively compared with before treatment, indicating that AYK103 not only has a good effect on canine breast cancer, but also the effect can be maintained for at least three months.
[0159] Fig.12 The results showed that the second dog treated was a golden retriever with one lesion. After 12 doses, the tumor shrank by 25%, which again demonstrated the effectiveness of AYK103 for canine breast cancer. AYK103 has good safety. The main adverse events after injection in the two treated dogs were local swelling, fever, vomiting, and mental depression at the injection site, which all recovered within 24-48 hours. No serious adverse events occurred, indicating that AYK103 has good safety.
[0160] Experimental Example 7
[0161] Experiment on treating mouse lung cancer with AYK103 prepared in Example 2.
[0162] Experimental methods
[0163] Six-week-old C57BL / 6J mice were subcutaneously inoculated with 6×10 5 LLC cells were used to establish a mouse lung cancer subcutaneous tumor model. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 6th day after tumor inoculation. The mice were randomly divided into 3 experimental groups according to the tumor volume, and the groups and medications were performed according to the method of Experimental Example 4. The general conditions such as the weight and diet of the animals were observed daily, the weight changes of the mice were monitored, and the changes in tumor size were detected every three days.
[0164] Experimental Results
[0165] After injection of AYK103, LLC tumor growth was inhibited, and the tumor growth rate in the AYK103 group was significantly lower than that in the negative control Vehicle group and the positive control chemotherapy drug cyclophosphamide CTX group ( Fig.13 ), the relative tumor inhibition rate was 73.2%.
[0166] Experimental Example 8
[0167] Experiment on treating mouse liver cancer with AYK103 prepared in Example 2.
[0168] Experimental methods
[0169] 6-week-old C57BL / 6J mice were subcutaneously inoculated with 2×10 6 H22 cells were used to establish a mouse liver cancer subcutaneous tumor model. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 4th day after tumor inoculation. The mice were randomly divided into three experimental groups according to the tumor volume, as follows: Vehicle (100μL / mouse), AYK103 group (100μL / mouse), Sorafenib group. The general conditions such as the weight and diet of the animals were observed daily, the weight changes of the mice were monitored, and the changes in tumor size were detected every three days.
[0170] Experimental Results
[0171] After injection of AYK103, H22 tumor growth was inhibited, and the tumor growth rate of the AYK103 group was significantly lower than that of the negative control Vehicle group and the positive control chemotherapy drug Sorafenib group ( Fig.14 ), the relative tumor inhibition rate was 62.6%.
[0172] Experimental Example 9
[0173] Experiment on treating mouse colon cancer with AYK103 prepared in Example 2.
[0174] 6-week-old C57BL / 6J mice were subcutaneously inoculated with 1×10 5 CT26 cells were used to establish a mouse liver cancer subcutaneous tumor model. The subcutaneous tumor volume of female C57BL / 6J mice was measured on the 11th day after tumor inoculation. The mice were randomly divided into three experimental groups according to the tumor volume, as follows: Vehicle (100μL / mouse), AYK103 group (100μL / mouse), CTX group. The general conditions such as the weight and diet of the animals were observed daily, the weight changes of the mice were monitored, and the changes in tumor size were detected every three days.
[0175] Experimental Results
[0176] After injection of AYK103, the growth of CT26 tumors was inhibited, and the tumor growth rate of the AYK103 group was significantly lower than that of the negative control Vehicle group and the positive control chemotherapy drug CTX group ( Fig.15 ), the relative tumor inhibition rate was 94.4%.
[0177] Experimental Example 11
[0178] Experiment on the treatment of mouse ovarian cancer abdominal metastasis model with AYK103 prepared in Example 2.
[0179] 6-week-old C57BL / 6J mice were intraperitoneally inoculated with 1×10 6 ID-8-Luci mouse epithelial ovarian cancer cells were used to establish a mouse ovarian cancer peritoneal metastasis model. On the third day after tumor implantation, the mice were divided into groups and administered drugs according to fluorescence imaging, as follows: Vehicle (100 μL / mouse), AYK103 group (100 μL / mouse). Fluorescence imaging was performed on the 6th and 9th days to track mouse ovarian cancer cells, and the general conditions of the animals, such as weight and diet, were observed daily, the weight changes of the mice were monitored, and the survival curve was continuously recorded.
[0180] Experimental Results
[0181] After injection of AYK103, the growth of ovarian cancer cells in the peritoneal cavity was significantly reduced ( Fig.16 ) and the survival rate of mice in the AYK103 group was still 100% 110 days after administration, while the survival rate of the control group was 40% ( Fig.17 ), indicating that AYK103 is effective in treating the peritoneal metastasis model of ovarian cancer in mice.
[0182] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of an immunomodulator in the preparation of a composition for treating animal cancer, characterized in that: The immunomodulator comprises: PolyIC and QS-21 in a mass ratio of (1.3-60):1, the cancer is breast cancer, melanoma, liver cancer, colon cancer, ovarian cancer or lung cancer, and the animal is dog, mouse or rat.
2. The use according to claim 1, characterized in that: The immunomodulator comprises: PolyIC and QS-21 in a mass ratio of (4-32):1; Preferably, the immunomodulator comprises: PolyIC and QS-21 in a mass ratio of (4-16):1; Preferably, the immunomodulator comprises: PolyIC and QS-21 in a mass ratio of (6-8):
1.
3. The use according to claim 1, characterized in that: The composition further comprises: a pharmaceutically acceptable carrier; Preferably, the carrier is a liposome; Preferably, the liposome is a cationic liposome; Preferably, the lipid component of the liposome is a phospholipid or a phospholipid-like molecule; Preferably, the phospholipids are selected from glycerophospholipids and sphingomyelins; Preferably, the phospholipid is selected from any one or a combination of at least two of DOPC, soybean lecithin, sunflower lecithin, DSPG, DPPC, HSPC, DSPC and EPC.
4. The use according to claim 3, characterized in that: In the composition, the mass ratio of PolyIC, QS-21 and liposome is (1.3-60):1:(15-25); Preferably, in the composition, the mass ratio of Poly IC, QS-21 and liposome is (6-10):1:(15-25).
5. The use according to claim 4, characterized in that: The liposome is prepared from 1,2-dioleoyl-3-trimethylammonium chloride propane, dioleoylphosphatidylcholine and cholesterol.
6. The use according to claim 3, characterized in that: The composition is prepared by the following method: blending the carrier with PolyIC and QS-21; Preferably, when the carrier is a liposome, the particle size of the liposome is 60 to 300 nm.
7. The use according to claim 3, characterized in that: The composition is a medicine; Preferably, the drug is administered by injection; Preferably, the drug is administered by intratumoral injection.
8. The use according to claim 7, characterized in that: The drug has any of the following uses: (1) Activate the immune response of the tumor microenvironment and reverse the tumor immunosuppressive microenvironment; (2) Inhibit tumor growth rate; (3) reduce tumor weight; (4) reduce tumor volume; Preferably, the use of the drug to activate the immune response of the tumor microenvironment includes: promoting tumor infiltration of CD4 T and CD8 T cells; Preferably, the use of the drug to activate the immune response of the tumor microenvironment is selected from at least one of the following: (1) Increase the number of cytotoxic T cells CD8+T in tumor tissue; (2) Increase the number of effector memory T cells CD8+T in tumor tissue; (3) Increase the number of CD4+ T helper cells in tumor tissue; (4) Increase the number of macrophages among antigen-presenting cells in tumor tissue; (5) Increase the number of dendritic cells among antigen-presenting cells in tumor tissue.
9. The use according to claim 1, characterized in that: The final concentration of the QS-21 in the composition is 50 to 300 μg / mL, and the final concentration of the Poly I:C is 400 to 3000 μg / mL.
10. Use of a composition in the preparation of a drug for treating animal cancer, characterized in that: The composition comprises: an immunomodulator and a pharmaceutically acceptable carrier, wherein the immunomodulator comprises: PolyIC and QS-21 in a mass ratio of (1.3-60):1, the cancer is breast cancer, melanoma, liver cancer, colon cancer, ovarian cancer or lung cancer, and the animal is a dog, a mouse or a rat; Preferably, the carrier is a liposome; Preferably, the liposome is a cationic liposome; Preferably, in the drug, the mass ratio of Poly IC, QS-21 and liposome is (1.3-60):1:(15-25); Preferably, in the composition, the mass ratio of Poly IC, QS-21 and liposome is (6-10):1:(15-25).
Citation Information
Patent Citations
Amphiphilic comb-shaped block graft copolymer-based ultrasonic contrast agent and preparation method thereof
CN111671922A
Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CN107073088A
Vaccine for treating chronic hepatitis B and preparation method and application thereof
CN109876140A
Immunologic adjuvant composition, cancer vaccine based on immunologic adjuvant composition and application of cancer vaccine
CN114887049A
Broad-spectrum tumor vaccine synergistic composition
CN115702927A
